Premium
RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMA
Author(s) -
Villa D.,
Hoster E.,
Hermine O.,
Klapper W.,
Szymczyk M.,
Bosly A.,
Unterhalt M.,
Freeman C. L.,
Scott D. W.,
Gerrie A. S.,
Savage K. J.,
Sehn L. H.,
Dreyling M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.62_2880
Subject(s) - medicine , rituximab , bendamustine , mantle cell lymphoma , autologous stem cell transplantation , hazard ratio , oncology , dhap , progression free survival , international prognostic index , transplantation , surgery , gastroenterology , lymphoma , confidence interval , chemotherapy , biochemistry , chemistry , enzyme